Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year.
Matinas BioPharma Hldgs Q2 EPS $(0.03), Inline
Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year.
Related Posts
Lennar’s Earnings: A Preview
September 13, 10:00 AM
Lennar (NYSE:LEN) is set to give its latest quarterly earnings report on Thursday, 2023-09-14. Here’s what investors need…
Why POET Technologies Stock Is Down 25% Today
November 30, 1:45 PM
POET Technologies Inc (NASDAQ: POET) shares are trading lower by 25% to $0.84 during Thursday's session after the company announced the pricing of its $1.4 million underwritten public offering of
Google Challenges India’s Antitrust Body Over Alleged Favoritism Towards Amazon
July 6, 7:47 AM
Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google criticized